Arix Bioscience plc

With a focus on late pre-clinical to clinical stage ventures and covering a diversified range of therapeutic areas, we partner with the most ambitious scientists and entrepreneurs to build companies around game-changing life science innovation

Experienced and collaborative team, with deep industry and scientific expertise

Team & Marketing Coordinator Public market access to revolutionary medical innovation

Find the latest share price, presentations, events and regulatory announcements here

Updates from Arix and our porfolio companies

Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy platform Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics